<?xml version="1.0" encoding="UTF-8"?>
<sec id="Sec5" class="sec">
 <div class="title" xmlns="http://www.w3.org/1999/xhtml">Pembrolizumab light-chain /PD-1 receptor interaction energy</div>
 <p id="Par21" xmlns="http://www.w3.org/1999/xhtml">The pembrolizumab light-chain is a little more distant of the PD-1 receptor than the heavy-chain one, as it can be inferred from its contribution to the total binding energy (
  <span class="italic">ε</span>
  <sub>20</sub>: −44.67 kcal mol
  <span class="sup">−1</span>; 
  <span class="italic">ε</span>
  <sub>40</sub>: −47.75 kcal mol
  <span class="sup">−1</span>), as well as from the number of pairs formed with the receptor (148). This is consistent with previous crystallographic results
  <span class="sup">
   <a ref-type="bibr" rid="CR25" href="#CR25">25</a>,
   <a ref-type="bibr" rid="CR26" href="#CR26">26</a>
  </span>. According to Fig. 
  <a rid="Fig6" ref-type="fig" href="#Fig6">6</a>, the most intense binding energies for the LC amino-acids is associated to the pair 
  <span class="italic">E</span>59
  <sub>
   <span class="italic">LC</span>
  </sub>-
  <span class="italic">K</span>131 (
  <span class="italic">ε</span>
  <sub>20</sub>: −11.90 kcal mol
  <span class="sup">−1</span>; 
  <span class="italic">ε</span>
  <sub>40</sub>: −9.70 kcal mol
  <span class="sup">−1</span>), being followed by the pairs 
  <span class="italic">S</span>95
  <sub>
   <span class="italic">LC</span>
  </sub>-
  <span class="italic">S</span>87 (
  <span class="italic">ε</span>
  <sub>20</sub>: −6.00 kcal mol
  <span class="sup">−1</span>; 
  <span class="italic">ε</span>
  <sub>40</sub>: −5.83 kcal mol
  <span class="sup">−1</span>), 
  <span class="italic">Y</span>53
  <sub>
   <span class="italic">LC</span>
  </sub>-
  <span class="italic">K</span>131 (
  <span class="italic">ε</span>
  <sub>20</sub>: −4.15 kcal mol
  <span class="sup">−1</span>; 
  <span class="italic">ε</span>
  <sub>40</sub>: −4.05 kcal mol
  <span class="sup">−1</span>), 
  <span class="italic">R</span>96
  <sub>
   <span class="italic">LC</span>
  </sub>-
  <span class="italic">R</span>86 (
  <span class="italic">ε</span>
  <sub>20</sub>: −1.47 kcal mol
  <span class="sup">−1</span>; 
  <span class="italic">ε</span>
  <sub>40</sub>: −2.62 kcal mol
  <span class="sup">−1</span>), and 
  <span class="italic">Y</span>36
  <sub>
   <span class="italic">LC</span>
  </sub>-
  <span class="italic">E</span>84 (
  <span class="italic">ε</span>
  <sub>20</sub>: −2.62 kcal mol
  <span class="sup">−1</span>; 
  <span class="italic">ε</span>
  <sub>40</sub>: −2.48 kcal mol
  <span class="sup">−1</span>).
  <div id="Fig6" class="fig">
   <span class="label">Figure 6</span>
   <div class="caption">
    <p>Graphical panel depicting the most relevant interactions involving the pembrolizumab light-chain residues 
     <span class="italic">Y</span>34, 
     <span class="italic">Y</span>36, 
     <span class="italic">Y</span>53, 
     <span class="italic">Y</span>57, 
     <span class="italic">E</span>59, 
     <span class="italic">E</span>95, 
     <span class="italic">R</span>96 and 
     <span class="italic">D</span>97.
    </p>
   </div>
   <div xlink:href="41598_2018_20325_Fig6_HTML" id="d29e1799" class="graphic" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  </div>
 </p>
 <p id="Par22" xmlns="http://www.w3.org/1999/xhtml">Figure 
  <a rid="Fig7" ref-type="fig" href="#Fig7">7</a> depicts some interactions made by the pembrolizumab light-chain residues linked to the PD-1 receptor. As one can see, the residue 
  <span class="italic">Y</span>36
  <sub>
   <span class="italic">LC</span>
  </sub> is surrounded by some charged residues (
  <span class="italic">E</span>84, 
  <span class="italic">D</span>85 and 
  <span class="italic">R</span>86) from the PD-1 receptor (Fig. 
  <a rid="Fig7" ref-type="fig" href="#Fig7">7a</a>). However, it only makes a single direct hydrogen bond with the main-chain carbonyl of the residue 
  <span class="italic">E</span>84, all the other interactions being non-conventional hydrogen bonds (
  <span class="italic">P</span>83 and 
  <span class="italic">R</span>86), and water-mediated hydrogen bonds. It would be inconsistent with the position occupied by this residue among the most energetic one of the pembrolizumab light-chain, if the number of pairs formed with 
  <span class="italic">Y</span>36
  <sub>
   <span class="italic">LC</span>
  </sub> (10) would not overcome it. The residue making the biggest number of pair-interaction is 
  <span class="italic">Y</span>34
  <sub>
   <span class="italic">LC</span>
  </sub>, namely 19. Notwithstanding, the residue 
  <span class="italic">Y</span>34
  <sub>
   <span class="italic">LC</span>
  </sub> shows a binding energy less than the 
  <span class="italic">Y</span>36
  <sub>
   <span class="italic">LC</span>
  </sub> one, due to an unfavorable interaction with the residue 
  <span class="italic">F</span>63 (
  <span class="italic">ε</span>
  <sub>20</sub>: 5.27 kcal mol
  <span class="sup">−1</span>; 
  <span class="italic">ε</span>
  <sub>40</sub>: 5.30 kcal mol
  <span class="sup">−1</span>).
  <div id="Fig7" class="fig">
   <span class="label">Figure 7</span>
   <div class="caption">
    <p>Intermolecular interactions of the most energetic pembrolizumab light-chain residues. (
     <span class="bold">a</span>) Interaction of the residue 
     <span class="italic">Y</span>36 with the most relevant residues of the receptor PD-1. (
     <span class="bold">b</span>) The same for the residues 
     <span class="italic">E</span>59 and 
     <span class="italic">S</span>95. Dashed lines in light blue (purple) (marine) represent direct (water-mediated) (non-conventional) hydrogen bonds.
    </p>
   </div>
   <div xlink:href="41598_2018_20325_Fig7_HTML" id="d29e1907" class="graphic" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  </div>
 </p>
 <p id="Par23" xmlns="http://www.w3.org/1999/xhtml">Although only five pair-interactions were calculated with the residue 
  <span class="italic">S</span>95
  <sub>
   <span class="italic">LC</span>
  </sub> within a radius of 8.0 Å, it shows one of the highest interaction energies of the drug’s light-chain. Similar to the residue 
  <span class="italic">Y</span>36
  <sub>
   <span class="italic">LC</span>
  </sub>, the majority of the surrounding residues make weak interactions, excluding 
  <span class="italic">S</span>87 which forms a water-mediated hydrogen bond through the hydroxyl group from both side-chains (see Fig. 
  <a rid="Fig7" ref-type="fig" href="#Fig7">7b</a>). It is also important to notice the attractive binding energy found to the 
  <span class="italic">R</span>96
  <sub>
   <span class="italic">LC</span>
  </sub>-
  <span class="italic">R</span>86 pair, even with the positively charged guanidine group from both amino-acids, assuming a conformation where they are very close. These two arginine residues are in a T-shaped stacking interaction, which favors an attractive bind
  <span class="sup">
   <a ref-type="bibr" rid="CR30" href="#CR30">30</a>
  </span>. Finally, the 
  <span class="italic">E</span>59
  <sub>
   <span class="italic">LC</span>
  </sub>-
  <span class="italic">K</span>131 pair forms the second salt bridge of the complex drug/receptor, depicting the highest individual interaction energy in the drug’s light-chain. This interaction is due to the negatively charged carboxyl group of the residue 
  <span class="italic">E</span>59
  <sub>
   <span class="italic">LC</span>
  </sub>, and the positively charged amine of the residue 
  <span class="italic">K</span>131 side-chain. It gives us the idea of the dynamic process which govern the interaction between the pembrolizumab Fab fragment and the extracellular region of the PD-1 receptor, such as the formation of a new salt bridge between the residues 
  <span class="italic">D</span>108
  <sub>
   <span class="italic">HC</span>
  </sub>-
  <span class="italic">K</span>131 whose opposite charges from the side-chain are very close (3.6 Å).
 </p>
 <p id="Par24" xmlns="http://www.w3.org/1999/xhtml">For completeness, we display in Fig. 
  <a rid="Fig8" ref-type="fig" href="#Fig8">8</a> the electrostatic potential isosurface with projected electron densities for the pembrolizumab amino-acids bound to some of the most important residues at the binding pocket site.
  <div id="Fig8" class="fig">
   <span class="label">Figure 8</span>
   <div class="caption">
    <p>Electrostatic potential isosurfaces with the projected electron densities for some pembrolizumab residues interacting with the most attractive residues of the receptor PD-1.</p>
   </div>
   <div xlink:href="41598_2018_20325_Fig8_HTML" id="d29e1990" class="graphic" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  </div>
 </p>
</sec>
